学术交流
首页  -  科学研究  -  学术交流  -  正文
学术报告—单克隆抗体药物产业的机遇和挑战

作者:编辑: 时间:2014-03-06 点击量:

时 间:2014年3月7日下午3:00 -4:30
地 点:东十一楼8797威尼斯老品牌四楼会议室
报告人:Yucai Peng, Ph.D. (彭育才博士,丽珠单抗生物制药公司副总经理、总工程师)Senior Vice President, Research and Product Development,Livzon MabPharm Inc.
主讲人简介:
        彭育才博士留学加拿大,获McGill University博士学位,回国前任美国百健生物制药公司部门高级经理,现任丽珠单抗生物制药公司副总经理、总工程师。他是分子生物和细胞生物学世界知名专家,在基因克隆、蛋白表达和功能分析,以及细胞株建立、蛋白纯化等方面的研究处于世界领先水平。Dr. Peng has more than fifteen years of experience in biologics and pharmaceutical development. In his current capacity as senior VP of Livzon MabPharm Inc, Dr. Peng is responsible for biologics process development, analytical/bioassay development, quality control, preclinical pD/pK/safety evaluation, IND filing, and clinical studies. Prior to joining Livzon, Dr. Peng was senior scientist and group leader at Biogen Idec, where he was responsible for assay development and technical support for manufacturing, QC, and CMC activities. Prior to Biogen Idec, Dr. Peng served at a target-based drug discovery company named Cetek Pharma as a senior scientist and project manager, responsible for gene cloning, protein production, and preclinical studies. Dr. Peng's formal education includes post-doctor training in Molecular Virology from New England Medical Center in Boston, a Ph. D. in Microbiology and Immunology from McGill University, a Master degree in medicine from Beijing University Medical School, and a B.S. in Biology from Wuhan University.
         欢迎有兴趣的老师和同学参加!


版权所有:8797威尼斯老品牌 - 威尼斯官网入口(东11楼)   邮编:430074


电话:027-87792072   领导邮箱:lifelife@hust.edu.cn